methylphenidate has been researched along with Dermatitis Medicamentosa in 8 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To identify and characterize cases of chemical leukoderma, an underrecognized adverse event, associated with the methylphenidate transdermal system (MTS) reported to the US Food and Drug Administration Adverse Event Reporting System (FAERS)." | 1.46 | Chemical Leukoderma Associated with Methylphenidate Transdermal System: Data From the US Food and Drug Administration Adverse Event Reporting System. ( Brinker, A; Cheng, C; Diak, IL; La Grenade, L; Levin, RL, 2017) |
| "Two children with attention deficit disorder treated with methylphenidate as a simple drug developed fixed drug eruption of the scrotum." | 1.28 | Fixed drug eruption of the scrotum due to methylphenidate. ( Ashkenazi, A; Cohen, HA; Frydman, M; Gross, S; Nussinovitch, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goyal, R | 1 |
| Arroyave, A | 1 |
| Malik, S | 1 |
| Kaya, I | 1 |
| Coskun, M | 2 |
| Cheng, C | 1 |
| La Grenade, L | 1 |
| Diak, IL | 1 |
| Brinker, A | 1 |
| Levin, RL | 1 |
| Tutkunkardas, MD | 1 |
| Zoroglu, S | 1 |
| Findling, RL | 1 |
| Katic, A | 1 |
| Rubin, R | 1 |
| Moon, E | 1 |
| Civil, R | 1 |
| Li, Y | 1 |
| Welsh, JP | 1 |
| Ko, C | 1 |
| Hsu, WT | 1 |
| Cohen, HA | 1 |
| Ashkenazi, A | 1 |
| Nussinovitch, M | 1 |
| Gross, S | 1 |
| Frydman, M | 1 |
| Hahn, HH | 1 |
| Schweid, AI | 1 |
| Beaty, HN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIIb, Long-Term, Open-Label, Multi-Center, Extension Study Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)[NCT00501293] | Phase 3 | 163 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00501293)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Antecedent Methylphenidate Transdermal System (MTS) | 81 |
| Antecedent Placebo | 39 |
Parent Global Assessment (PGA) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00501293)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Antecedent Methylphenidate Transdermal System (MTS) | 69 |
| Antecedent Placebo | 31 |
The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. (NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Baseline measure | 6 months | Change from baseline at 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 16.0 | 13.5 | -2.6 |
| Antecedent Placebo | 27.4 | 14.5 | -12.9 |
The Conner's Parent rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true) with a total score ranging from 0 to 81. Higher scores are indicative of increased ADHD. This scale allows parents to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior. (NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Baseline measure | 6 months | Change from baseline at 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 26.5 | 22.5 | -3.9 |
| Antecedent Placebo | 42.3 | 24.6 | -17.7 |
The Youth Quality of Life-research version (YQOL-R) is a validated 56-item generic instrument for comparing quality of life of adolescents across condition groups that scores each question on a scale from 0 (never) to 4 (very often). The YQOL scores are transformed to a 0-100 scale for easy interpretability. Higher scores indicate better quality of life. (NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Baseline measure | 6 months | Change from baseline at 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 82.4 | 85.0 | 1.9 |
| Antecedent Placebo | 80.9 | 84.6 | 2.7 |
Dermal reactions were graded on a scale ranging from 0 (no irritation) to 7 (strong reaction) for observed findings of erythema, edema, papules, and vesicles. (NCT00501293)
Timeframe: 6 months
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 0 (No evidence of irritation) | 1 (Minimal erythema) | 2 (Definite erythema) | 3 (Erythema and papules) | 4 (Definite edema) | 5 (Erythema, edema, and papules) | 6 (Vesicular eruption) | 7 (Strong reaction beyond test site) | No dermal evaluation | |
| Antecedent MTS and Antecedent Placebo | 23 | 42 | 82 | 6 | 0 | 4 | 0 | 0 | 5 |
(NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline measure | 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 69.4 | 67.9 |
| Antecedent Placebo | 67.2 | 68.9 |
QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate(e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation. (NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | msec (Mean) | |
|---|---|---|
| Baseline measure | 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 391.8 | 395.3 |
| Antecedent Placebo | 393.2 | 393.5 |
Post Sleep Questionnaire (PSQ) overall rating of quality of sleep. There are 5 rating responses ranging from very poor to very good. No numbers are associated with the rating responses. (NCT00501293)
Timeframe: 6 months
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Very poor | Poor | Average | Good | Very Good | |
| Antecedent Methylphenidate Transdermal System (MTS) | 1 | 6 | 34 | 27 | 23 |
| Antecedent Placebo | 1 | 3 | 10 | 15 | 9 |
(NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | beats per minute (Mean) | |
|---|---|---|
| Baseline measure | 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 80.4 | 81.7 |
| Antecedent Placebo | 74.3 | 78.9 |
(NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline measure | 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 113.4 | 115.3 |
| Antecedent Placebo | 113.0 | 115.9 |
(NCT00501293)
Timeframe: Baseline and 6 months
| Intervention | lb (Mean) | |
|---|---|---|
| Baseline measure | 6 months | |
| Antecedent Methylphenidate Transdermal System (MTS) | 127.05 | 134.55 |
| Antecedent Placebo | 131.95 | 124.78 |
1 trial available for methylphenidate and Dermatitis Medicamentosa
| Article | Year |
|---|---|
A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder.
Topics: Administration, Cutaneous; Adolescent; Appetite; Attention Deficit Disorder with Hyperactivity; Cent | 2010 |
7 other studies available for methylphenidate and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Urticaria and Angioedema Secondary to Methylphenidate Exposure in a Young Child.
Topics: Central Nervous System Stimulants; Drug Eruptions; Humans; Methylphenidate | 2015 |
Diffuse Maculopapular Rash With Increasing Dosage of Methylphenidate.
Topics: Central Nervous System Stimulants; Child; Dose-Response Relationship, Drug; Drug Eruptions; Humans; | 2016 |
Chemical Leukoderma Associated with Methylphenidate Transdermal System: Data From the US Food and Drug Administration Adverse Event Reporting System.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Central Nervous System Stimulants; Child | 2017 |
OROS methylphenidate-induced skin eruptions.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Action Pre | 2009 |
Lymphomatoid drug reaction secondary to methylphenidate hydrochloride.
Topics: Adult; Antigens, CD; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2008 |
Fixed drug eruption of the scrotum due to methylphenidate.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Drug Eruptions; Genital Diseases, Male; Humans | 1992 |
Complications of injecting dissolved methylphenidate tablets.
Topics: Biopsy; Drug Eruptions; Endocarditis, Bacterial; Foreign Bodies; Heart Valve Diseases; Injections, I | 1969 |